A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

The study is being conducted to determine if cenicriviroc mesylate (CVC) will decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta.

Start Date30 May 2023

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

NCT04334915 / WithdrawnPhase 2IIT

A Multicenter, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

The purpose of this study is to evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation in people living with HIV.

Start Date22 Nov 2022

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

NCT04593940 / CompletedPhase 3IIT

Randomized Master Protocol for Immune Modulators for Treating COVID-19

ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective.
The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.

Start Date15 Oct 2020

Sponsor / Collaborator

Biomedical Advanced Research and Development Authority (BARDA)

[+1]

100 Clinical Results associated with Cenicriviroc mesylate

100 Translational Medicine associated with Cenicriviroc mesylate

100 Patents (Medical) associated with Cenicriviroc mesylate

329

Literatures (Medical) associated with Cenicriviroc mesylate

01 Jan 2024·Osteoarthritis and cartilage

CCR2 monocytes as therapeutic targets for acute disc herniation and radiculopathy in mouse models

Article

Author: Xiao, Li ; Shi, Weibin ; Sung, Sun-Sang J ; Jin, Li ; Manley, Brock J ; Kerrigan, Jason R ; Zhang, Yi ; Huang, Wendy ; Kuan, Chia-Yi ; Chi, Jialun ; Oh, Eunha G ; Li, Xudong

OBJECTIVE:

Back pain and radiculopathy caused by disc herniation are major health issues worldwide. While macrophages are key players in disc herniation induced inflammation, their roles and origins in disease progression remain unclear. We aim to study the roles of monocytes and derivatives in a mouse model of disc herniation.

METHODS:

Using a CCR2-CreER; R26R-EGFP (Ai6) transgenic mouse strain, we fate-mapped C-C chemokine receptor type 2 (CCR2) expressing monocytes and derivatives at disc herniation sites, and employed a CCR2^RFP/RFP mouse strain and a CCR2-specific antagonist to study the effects of CCR2⁺ monocytes on local inflammatory responses, pain level, and disc degeneration by immunostaining, flow cytometry, and histology.

RESULTS:

CCR2⁺ monocytes (GFP⁺) increased at the sites of disc hernia over postoperative day 4, 6, and 9 in CCR2-CreER; Ai6 mice. F4/80⁺ cells increased, and meanwhile, CD11b⁺ cells trended downward. Co-localization analysis revealed that both GFP⁺CD11b⁺ and GFP⁺F4/80⁺ constituted the majority of CD11b⁺ and F4/80⁺ cells at disc hernia sites. Fluorescence activated cell sorter purified GFP⁺ cells exhibited higher cytokine expressions than GFP^- cells. Inhibition of CCR2 signaling reduced infiltration of monocytes and macrophages, alleviated pain, maintained disc height, and reduced osteoclast activity in adjacent cortical bone for up to 1 month.

CONCLUSION:

Our findings suggest that circulating CCR2⁺ monocytes play important roles in initiating and promoting the local inflammatory responses, pain sensitization, and degenerative changes after disc herniation, and thus may serve as therapeutic targets for disc herniation induced back and leg pain.

01 Jan 2024·Experimental animals

CCR2 antagonist attenuates calcium oxalate-induced kidney oxidative stress and inflammation by regulating macrophage activation

Article

Author: Wang, Xinpeng ; Liu, Chunyu ; Xie, Linguo

C-C chemokine receptor type 2 (CCR2) is a monocyte chemokine associated with oxidative stress and inflammation. Kidney stones (KS) are composed of calcium oxalate (CaOx), which trigger renal oxidative stress and inflammatory. This study aims to evaluate the effects of CCR2 on KS in vivo and in vitro. Eight-week-old male C57BL/6J mice were intraperitoneally injected with glyoxylate (GOX) daily to establish a KS model, and along with CCR2 antagonist (INCB3344) treatment on days 2, 4, and 6. The results showed that CCR2 antagonist reduced renal injury markers (blood urea nitrogen and serum creatinine), alleviated renal tubular injury and CaOx crystal deposition. CCR2 antagonist also decreased CCR2 expression induced by GOX treatment and increased Nrf2 expression. GOX treatment promoted malondialdehyde (MDA) production, decreased glutathione (GSH) content, and inhibited catalase (CAT) and superoxide dismutase (SOD) activity, however, CCR2 antagonist attenuated the above effects of GOX. CCR2 antagonist had inhibitory effects on GOX-induced inflammatory cytokine expression (IL1B, IL6 and MCP1), and inhibited apoptosis by increasing Bcl-2 expression and decreasing Bax and cleaved-caspase 3 expression. In vitro experiments were performed by co-culture model of CaOx-induced damaged HK-2 cells and macrophage-like THP-1 cells. CCR2 antagonist inhibited CaOx-induced THP-1 cell M1 polarization by decreasing the TNF-α, IL6 and iNOS levels, and further alleviated CaOx-induced oxidative stress damage, inflammatory response and apoptosis of HK-2 cells. The study suggests that CCR2 antagonist may be resistant to CaOx crystals-induced oxidative stress and inflammation by inhibiting macrophage M1 polarization.

01 Jan 2024·Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

Article

Author: Landgren, Henrik ; Neuschwander-Tetri, Brent A. ; Bedossa, Pierre ; Alkhouri, Naim ; Abdelmalek, Manal F. ; Wai-Sun Wong, Vincent ; Sanyal, Arun J. ; Tacke, Frank ; Anstee, Quentin M. ; Park, Grace S. ; Rodriguez-Araujo, Gerardo

BACKGROUND AND AIMS:

Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Herein, we report efficacy and safety results from the phase III study.

METHODS:

The AURORA (A Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH) study was a phase III, randomized, double-blind, placebo-controlled, 2-part study of patients with NASH and stage 2/3 liver fibrosis. Adults, 18-75 years of age, were randomized to CVC 150 mg or placebo once daily for 12 months (part 1) or 60 months (part 2). Liver biopsies were performed at screening, month 12, and early study discontinuation or termination. The primary efficacy endpoint was the proportion of patients with fibrosis improvement ≥1 stage without worsening of steatohepatitis at month 12 relative to screening. Adverse events were assessed throughout the study.

RESULTS:

A total of 1778 patients were randomized and discontinued (part 1: n = 1293; part 2: n = 485). In part 1, at month 12, a similar proportion of patients receiving CVC or placebo achieved the primary endpoint (22.3% vs 25.5%; odds ratio, 0.84; 95% confidence interval, 0.63-1.10; P = .21) and complete resolution of steatohepatitis without worsening of fibrosis (23.0% vs 27.2%; P = .21). The safety profile was generally comparable across treatment groups.

CONCLUSIONS:

This study did not demonstrate the efficacy of CVC for treating liver fibrosis assessed by histology in adults with NASH; however, CVC was safe and well tolerated in patients with NASH and liver fibrosis. (ClinicalTrials.gov, Number: NCT03028740).

News (Medical) associated with Cenicriviroc mesylate

11 Jul 2023

·www.pharmaceutical-technology.com

Covid-19: Anti-inflammatory drugs do not lead to a swifter hospital exit

Robert Barrie There were still over 6,000 hospitalisations due to Covid-19 in the past week in the US. Unvaccinated adults are fives times more likely to die from the disease. Image credit: Shutterstock/Gorodenkoff Anti-inflammatory drugs may reduce deaths due to Covid-19, but they do not help speed up the recovery for those in hospital, according to a recent study. Results from the study , published in The Journal of the American Medical Association , demonstrated that giving abatacept , cenicriviroc, or Johnson and Johnson’s Remicade (infliximab) in addition to standard of care did not decrease time to recovery for patients hospitalised with Covid-19 pneumonia. The standard of care included in this study involved Gilead Sciences’ Veklury (remdesivir) and the corticosteroid dexamethasone. Recommended Reports Reports Artificial Intelligence in Healthcare: Non-Invasive Physiological Monitoring GlobalData Reports Nitric Oxide Synthase (NO Synthase or NOS or EC 1.14.13.39) Drugs in Development by Therapy Areas... GlobalData View all Companies Intelligence SOC Co., Ltd Roche S.A. Genentech, Inc. JAMA Sp. z o.o. View all Patients who took either one of the three drugs recovered after a similar number of days compared to those who were on placebo. The investigators also measured mortality across the sub-studies by day 28 – which did show slight differences, though not statistically significant. Abatacept and Remicade led to a narrow decrease in patient deaths – a 4.1% and 4.4% difference respectively, whilst the cenicriviroc group’s mortality rose by 1.9%. A limitation with the latter group was adherence, however, as cenicriviroc is orally administered, unlike abatacept and Remicade which are infused intravenously. Though the study did not meet any endpoints, the authors note that “expanding treatment armament” is important as SARS-CoV-2 variants may always emerge that may evade antiviral treatments. Although the World Health Organization (WHO) declared an end to the Covid-19 public health emergency, there were still over 6,000 hospitalisations due to the disease in the past week in the US. Based on statistics from March 2023, the Centers for Disease Control and Prevention state that unvaccinated adults are around five times more likely to die from Covid-19. The JAMA trial remains a helpful scaffold with the investigators saying that other previous large-scale Covid-19 studies have not concurrently evaluated multiple agents whilst simultaneously providing a shared placebo group. Still, the study was a randomised, double-masked, placebo-controlled clinical trial (NCT04593940) that enrolled almost 2,000 patients, in comparison to other smaller open-label studies that explored similar questions. However, a limitation of this study itself was that it took place before the SARS-CoV-2 Omicron variant became prevalent. During the pandemic, Covid-19 patients were prescribed the corticosteroid dexamethasone, with research showing that the drug reduces mortality for patients on respiratory support. There was interest in whether giving additional, targeted anti-inflammatory agents could complement steroid action. Tocilizumab, marketed as Actemra by Roche subsidiary Genentech, was given emergency authorisation by the US Food and Drug Administration (FDA) for treating hospitalised Covid-19 patients receiving systemic corticosteroids. “One of the fundamental questions of early Covid-19 research was whether we could dampen the inflammatory process using existing anti-inflammatory drugs,” said Dr. William G. Powderly, national principal investigator of the trial. “Our data suggest that two of the drugs we studied can be given to reduce mortality in severely ill patients. We hope this study will be helpful in revising guidelines for best practices in treating patients hospitalized with Covid-19.”

Clinical StudyClinical ResultDrug Approval

26 Jun 2023

·www.prnewswire.com

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

HANGZHOU and SHAOXING, China, June 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (CHB) patients with 12-week treatment at European Association for the Study of the Liver (EASL) CONGRESS 2023. The summary of the abstract is shown as below: Title: A phase 2 study of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B patients with 12-week treatment Presenter: Jinzi J. Wu, Ph.D. Principal Investigator: Prof. Jinlin Hou, Nanfang Hospital of Southern Medical University Poster Number: SAT-201 Category: Viral Hepatitis B and D Study Design: This Phase 2 trial (NCT05107778) was a multi-center, randomized, single-blind, placebo-controlled study conducted in China. Forty-three HBeAg negative, hepatitis B virus (HBV) DNA Results: In total, 122, 119, and 107 adverse events (AEs) were reported in 10 mg ASC42, 15 mg ASC42 and PBO cohorts, respectively, and most AEs (94.3%) were mild (grade 1) or moderate (grade 2) in severity. One subject in 15 mg ASC42 cohort experienced a grade 3 serious AE (SAE) of liver function injury with a final outcome of recovered. Pruritus is the most common AE, and study drug-related pruritus was reported in 1 (6.7%), 7 (50%) and 0 (0%) subjects in 10 mg ASC42, 15 mg ASC42 and PBO cohorts, respectively. Pruritus rate of 10 mg ASC42 (6.7%) is lower than other FXR agonists in non-alcoholic steatohepatitis (NASH) patients. Conclusion: In CHB patients, 12-week treatment of 10 mg ASC42 in combination of PEG-IFN-α-2a and ETV was safe and well-tolerated and showed minimum and mild pruritus (6.7%). Previous study indicated that in healthy subjects, 14-day treatment of ASC42 alone demonstrated 471%~1,780% increase of fibroblast growth factor 19 (FGF19) and 53%~91% decrease of 7α-hydroxy-4-cholesten-3-one (C4) at a dose range of 5 mg~15 mg. Data suggest that at the therapeutic dose of 10 mg, the novel FXR agonist ASC42 is differentiated from other FXR agonists in terms of pruritus. [1]. Data on file [2]. Younossi Z.M., Ratziu V., Loomba R., et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [J]. The Lancet, 2019, 394(10215): 2184-96.DOI: 10.1016/s0140-6736(19)33041-7 [3]. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B [J]. N Engl J Med, 2005, 352(26): 2682-95.DOI: 10.1056/NEJMoa043470 [4]. Loomba R., Noureddin M., Kowdley K.V., et al. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH [J]. Hepatology, 2021, 73(2): 625-43.DOI: 10.1002/hep.31622 [5]. Anstee Q.M., Lucas K.J., Francque S., et al. Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study [J]. Hepatology, 2023.DOI: 10.1097/hep.0000000000000439 About EASL EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2022, EASL serves 4,900 members from 112 countries. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 23 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit . SOURCE Ascletis Pharma Inc.

Clinical ResultPhase 2Phase 3

02 May 2023

·www.prnewswire.com

Viscient Biosciences Announces First Drug Discovered in 3D Bioprinted Models

Company's NASH Drug Expected to Enter Clinic in 2024 SAN DIEGO, May 2, 2023 /PRNewswire/ -- Viscient Bio, Inc. ("Viscient") today announced it has identified the world's first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. Viscient expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the US population. NASH can often lead to hepatocellular carcinoma or liver failure. Due to the devastating effects of NASH on patients and its wide prevalence, analysis have projected future pharma industry revenues for the drug in the tens of billions of dollars per year. Continue Reading Viscient's lead compound is an orally delivered small molecule designed to hit a novel target identified in 3D bioprinted and other 3D tissue models of disease. In preclinical studies, the drug has proven to be well tolerated. In Viscient's models of disease, the compound shows reduction of fibrosis as measured by histological evidence similar to that used for human liver biopsy. Using the same model, fibrosis reduction is also seen for obeticholic acid and resmetirom, while no fibrosis reduction is seen for drugs such as cenicriviroc, selonsertib, and elafibranor. The newly discovered target is predominantly expressed in liver tissue. Failed NASH drugs never would have been put in humans based on what can be clearly seen in these models. Tweet this "It is long past time to displace the model of drug development reliant on proof of activity in animals," said Viscient chief executive officer Keith Murphy. "Viscient's trailblazing work has resulted in 3d cellular human models of disease in which the performance of previously tested compounds has matched clinical results. Failed NASH drugs never would have been put in humans based on what can be clearly seen in these models. Our novel compound shows fibrosis reduction in these models, as do NASH drugs known to work in Phase 3, and we are excited to move this lead program forward." The lead compound's clear reduction of fibrosis in Viscient's NASH models is promising because Viscient's 3D models of NASH have shown extremely high correlation with clinical results in patients. The model demonstrates fibrosis reduction for known clinical compounds tested by pharma companies that have that effect in humans, while revealing lack of fibrosis reduction for compounds that failed in Phase 2 or Phase 3 for NASH. The model is accurate in predicting both successes and failures among clinical compounds tested to date. The gene expression of Viscient's models is also well correlated with that seen in disease samples from patients. Though tested post-hoc, the results are not backfit, as the model was finalized before testing of any clinical compounds was conducted. According to the Biotechnology Innovation Organization's 2021 report, only 7.9% of drugs that enter clinical trials are approved for human use. Viscient Biosciences believes that we can achieve a significantly better clinical translation rate than that using more relevant 3D human tissue models of disease, leading to more successes and lower drug development costs per approved drug. Viscient is leading the world in creation of human tissue models with accurate disease relevance, and demonstrating the application of these models to drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for NASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in 2024. Viscient's 3D models of NASH have shown extremely high correlation with clinical results in patients, demonstrating fibrosis reduction for compounds that have that effect in humans while revealing lack of fibrosis reduction for compounds that failed in Phase 2 or Phase 3 for NASH. The gene expression of Viscient's models is also well correlated with that seen in disease samples from patients. Utilizing these 3D human tissues as dynamic models of healthy and diseased human biology for drug development, the company identifies opportunities both for novel therapeutic development and the in-licensing and repurposing of drugs. SOURCE Viscient Bio, Inc.

Clinical Result

100 Deals associated with Cenicriviroc mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D09879	-	-	DB11758

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 3	US	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	AU	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	AT	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	BE	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	BR	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	CA	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	CL	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	FR	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	DE	Tobira Therapeutics, Inc.	05 Apr 2017
Fibrosis, Liver	Phase 3	GR	Tobira Therapeutics, Inc.	05 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04593940 (Pubmed)	Phase 3	COVID-19	1,971	Abatacept	ftltjcfjgv(nzvpwsfiwj) = cafapkxfpg iaqsejvaty (shfqkufwvr )	-	10 Jul 2023
				Cenicriviroc	ftltjcfjgv(nzvpwsfiwj) = udsucwrkhf iaqsejvaty (shfqkufwvr )
NCT04593940 (CTgov)	Phase 3	COVID-19	1,971	Infliximab (Standard of Care + Infliximab)	agkiwoktdn(hvtmbujmxl) = yqjvmuahgr yxgpukfxkb (qqtnxygqif, tcltlexfcv - nsvcvudkwi) View more	-	21 Apr 2023
				Placebo (Standard of Care + Infliximab Matching Placebo)	agkiwoktdn(hvtmbujmxl) = uiutsghnbo yxgpukfxkb (qqtnxygqif, pjfsxznsqu - uzzxsrbnow) View more
NCT03028740 (AURORA, Pubmed)	Phase 3	Nonalcoholic Steatohepatitis	1,778	Cenicriviroc 150 mg	zlgrcbyixg(evzedxesmu): odds ratio = 0.84 (95% CI, 0.63 - 1.1)	Negative	13 Apr 2023
				Placebo
NCT03028740 (AURORA, CTgov)	Phase 3	Fibrosis, Liver \| Nonalcoholic Steatohepatitis	1,778	Placebo (Placebo)	oneqgwgyid(vdmhuyvhxd) = uxdkwoaglz mfnatialsk (zycjjbfaue, tvznanmlit - fcogpskxyw) View more	-	10 Mar 2022
				Cenicriviroc (Cenicriviroc 150 mg)	oneqgwgyid(vdmhuyvhxd) = fdvejcrkjo mfnatialsk (zycjjbfaue, hqbldrgwmx - jfgiparvcs) View more
NCT03059446 (CTgov)	Phase 2	Fibrosis, Liver \| Nonalcoholic Steatohepatitis \| Liver Cirrhosis	167	Cenicriviroc	asotxbnntd(vogatexzjt) = bhupvykbit aqtechacpl (gksozquuiz, vjphtlszru - fhpgoaiaqj) View more	-	02 Feb 2022
NCT02653625 (PERSEUS, Pubmed \| Hepatol Commun) Manual	Phase 2	Cholangitis, Sclerosing	20	cenicriviroc	fgrbxrsicw(bqppqtwlpm) = oxorewhaic ljqbwvobmj (mylgcryxha ) View more	Positive	22 Dec 2020
NCT02128828 (H020, CTgov)	Phase 2	Cognitive Dysfunction \| AIDS Dementia Complex	20	cenicriviroc	obzoyocmsl(exzptkefkh) = uxbtjyhmae pqiiickdau (nqvzzetkin, vynlyihywk - hoiwtmwnld) View more	-	20 Aug 2020
NCT02330549 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Prediabetic State \| Metabolic dysfunction-associated steatotic liver disease	45	Cenicriviroc 150 mg (Cenicriviroc 150 mg)	jezualtahx(jxtzlqcbqb) = wgoxsjqubf rgqrswehpv (rywuwyfxqq, aoinnnnkgj - cmjjyzgiun) View more	-	11 Oct 2019
				Placebo (Placebo)	jezualtahx(jxtzlqcbqb) = ehenqjikbs rgqrswehpv (rywuwyfxqq, aqxeknzhjm - degxngzdry) View more
NCT02217475 (CENTAUR, EASD2019)	Phase 2	Nonalcoholic Steatohepatitis high-sensitivity C-reactive protein \| fibrinogen \| interleukin (IL)-6 ... View more	289	Cenicriviroc 150 mg	pvkggkdjnb(xazeevykyx) = adverse events were comparable for CVC and placebo; no deaths occurred wwhwhiudxu (ehidpkgpny )	Positive	19 Sep 2019
				Placebo
CENTAUR (ADA2019)	Not Applicable	Nonalcoholic Steatohepatitis	289	Cenicriviroc 150 mg	ngahhwfnjq(rsufkmgjvr) = fvlyvlarss enxztwbjwg (dclunwxohz )	-	01 Jun 2019
				Placebo	ngahhwfnjq(rsufkmgjvr) = yossvwyhjz enxztwbjwg (dclunwxohz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis